Citigroup Inc Rigel Pharmaceuticals Inc Transaction History

Citigroup Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.12 - $1.57 $4,903 - $6,873	4,378 Added 15.59%	32,460 $48,000
Q4 2023 Feb 09, 2024	BUY	$0.72 - $1.56 $20,147 - $43,653	27,983 Added 28265.66%	28,082 $40,000
Q3 2023 Nov 09, 2023	SELL	$1.07 - $1.39 $54,441 - $70,723	-50,880 Reduced 99.81%	99 $0
Q2 2023 Aug 10, 2023	SELL	$1.12 - $1.82 $81,851 - $133,009	-73,082 Reduced 58.91%	50,979 $65,000
Q1 2023 May 11, 2023	BUY	$1.25 - $2.0 $126,008 - $201,614	100,807 Added 433.5%	124,061 $163,000
Q4 2022 Feb 09, 2023	SELL	$0.67 - $11.9 $7,344 - $130,447	-10,962 Reduced 32.04%	23,254 $34,000
Q3 2022 Nov 10, 2022	SELL	$1.1 - $12.2 $1.69 Million - $18.8 Million	-1,538,805 Reduced 97.82%	34,216 $40,000
Q2 2022 Aug 10, 2022	BUY	$0.67 - $3.19 $987,299 - $4.7 Million	1,473,582 Added 1481.9%	1,573,021 $1.78 Million
Q1 2022 May 12, 2022	SELL	$2.22 - $3.45 $690,546 - $1.07 Million	-311,057 Reduced 75.78%	99,439 $297,000
Q4 2021 Feb 10, 2022	BUY	$2.36 - $3.57 $462,194 - $699,166	195,845 Added 91.24%	410,496 $1.09 Million
Q3 2021 Nov 10, 2021	BUY	$3.5 - $4.5 $751,278 - $965,929	214,651 New	214,651 $779,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.81B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.